Barriers of Treating EGFR-Mutant NSCLC With Adjuvant Osimertinib
Nathan Pennell, MD, PhD, discusses the cost-effectiveness of adjuvant osimertinib in resected EGFR-mutant non-small cell lung cancer.
Nathan Pennell, MD, PhD, a medical oncologist at the Cleveland Clinic, discusses the cost-effectiveness of adjuvant osimertinib (Tagrisso) in resected EGFR-mutant non-small cell lung cancer (NSCLC).
According to Pennell, at a 5% improvement in survival, osimertinib has a cost effectiveness ratio of $317,000, much higher than the commonly drug cost of $195,000 in the United States. This means, at the current cost, adjuvant osimertinib does not appear to be cost effective in this patient population.
However, the hope is that osimertinib turns out to be much more effective than previously reported, according to Pennell. If the effectiveness rate is between 25% to 30%, the agent would prove to be cost effective at the current standard. Additionally, if osimertinib was half the price, the drug would be cost-effective at 5%.
Zipalertinib Shows Promise in Heavily Pretreated EGFR Exon 20-Mutated NSCLC
September 14th 2024Zipalertinib appeared safe and effective in the treatment of heavily pretreated patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed on or after amivantamab.
Read More
Amivantamab/Lazertinib Shows Potential in Atypical EGFR-Mutant Lung Cancer
August 20th 2024Byoung Chul Cho, MD, PhD, discussed findings from cohort C of the CHYRSALIS-2 study exploring amivantamab plus lazertinib in patients with non–small cell lung cancer with uncommon EGFR mutations.
Read More
FDA Clears Lazertinib/Amivantamab for First-Line EGFR-Mutated NSCLC
August 20th 2024Lazertinib and amivantamab as a first-line treatment for patients with locally advanced or metastatic non–small cell lung cancer with specific EGFR mutations demonstrated superior efficacy compared with standard treatment.
Read More
